Q-omics provides the consensus-scored BCAS2 profile across patient tissues and cancer cell-line models. BCAS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, BCAS2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, BCAS2 protein abundance shows 44,039 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, KICH, and LSCC as cancer lineages where BCAS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAS2 survival associations across molecular data types. BCAS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAS2 RNA expression–survival associations across cancer types. High BCAS2 expression shows unfavorable associations in SCLC, LGG, LIHC and KICH, but favorable associations in KIRC and READ. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for BCAS2 RNA expression.
This table summarizes BCAS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BCAS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAS2 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher BCAS2 RNA expression in normal versus tumor tissue (log2 FC = −1.768, t-test p < 0.001).
This table shows molecular features associated with BCAS2 in patient tissues and cancer cell lines. In patient samples, BCAS2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCAS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
